This post was originally published on this site
Abbott Laboratories (NYSE:ABT) reported stable third quarter profits on Wednesday, with earnings of $1.44 billion or 82 cents per share. The adjusted earnings, which came in at $1.14 per share, surpassed market estimates. Despite a slight decline in revenue from $10.41 billion a year ago to $10.14 billion, the figures still exceeded the projected market consensus of $9.82 billion.
Organic sales saw an increase of 14%, once factors such as the acquisition of Cardiovascular Systems (NASDAQ:CSII), declining COVID-19 tests, and foreign exchange translations were excluded. The company’s infant formula business experienced a nearly 21% surge in global sales following the voluntary recall of Similac, indicating a recovery in the market.
Additionally, Abbott’s adult nutrition sector, led by the Ensure nutrition drink, reported an 11% sales increase. These positive developments come even as Abbott exits its pediatric nutrition business in China.
In light of these results, Abbott has revised its full-year earnings guidance and raised the midpoint of its adjusted earnings outlook. This move suggests a positive trajectory for the company despite some challenges in the past quarter.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
